191 related articles for article (PubMed ID: 18381452)
1. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.
Worschech A; Kmieciak M; Knutson KL; Bear HD; Szalay AA; Wang E; Marincola FM; Manjili MH
Cancer Res; 2008 Apr; 68(7):2436-46. PubMed ID: 18381452
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
Kmieciak M; Knutson KL; Dumur CI; Manjili MH
Eur J Immunol; 2007 Mar; 37(3):675-85. PubMed ID: 17304628
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
[TBL] [Abstract][Full Text] [Related]
4. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
6. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
7. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals".
Manjili MH; Arnouk H; Knutson KL; Kmieciak M; Disis ML; Subjeck JR; Kazim AL
Breast Cancer Res Treat; 2006 Apr; 96(3):233-41. PubMed ID: 16211331
[TBL] [Abstract][Full Text] [Related]
8. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.
Kmieciak M; Morales JK; Morales J; Bolesta E; Grimes M; Manjili MH
Cancer Immunol Immunother; 2008 Sep; 57(9):1391-8. PubMed ID: 18278493
[TBL] [Abstract][Full Text] [Related]
9. T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors.
Wang LX; Plautz GE
Breast Cancer Res Treat; 2012 Jul; 134(1):61-70. PubMed ID: 22173696
[TBL] [Abstract][Full Text] [Related]
10. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML
J Immunol; 2006 Jul; 177(1):84-91. PubMed ID: 16785502
[TBL] [Abstract][Full Text] [Related]
11. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
12. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
Singh R; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
[TBL] [Abstract][Full Text] [Related]
14. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
15. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
16. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
17. Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.
Aricò E; Sestili P; Carpinelli G; Canese R; Cecchetti S; Schiavoni G; D'Urso MT; Belardelli F; Proietti E
Oncotarget; 2016 Sep; 7(37):59754-59765. PubMed ID: 27486759
[TBL] [Abstract][Full Text] [Related]
18. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.
Weiss VL; Lee TH; Song H; Kouo TS; Black CM; Sgouros G; Jaffee EM; Armstrong TD
PLoS One; 2012; 7(2):e31962. PubMed ID: 22359647
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
